Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Yardley on the Utility of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer

January 16th 2020

Denise Yardley, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor

Predictive Assays Help Personalize Care in Early-Stage HR+ Breast Cancer

January 15th 2020

Stephanie L. Graff, MD, discusses the importance of using genomic risk to tailor treatment to patients with early-stage hormone receptor-positive, HER2-negative disease, the benefit of extended endocrine therapy, and ongoing research with CDK4/6 inhibitors and immunotherapy.

Dr. Graff on Extended Adjuvant Therapy in Early-Stage HR+ Breast Cancer

January 15th 2020

Stephanie L. Graff, MD, discusses the utility of extended adjuvant therapy in women with early-stage hormone receptor-positive, HER2-negative breast cancer.

Navigating Frontline Treatment With CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

January 14th 2020

Denise Yardley, MD, discusses the implications of CDK4/6 inhibitors in hormone receptor-positive/HER2-negative breast cancer. 

HER2+ Breast Cancer: Future Treatment Landscape

January 11th 2020

Practical Advice on Treating HER2+ Metastatic Breast Cancer

January 11th 2020

Targeting HER2 Outside of Breast Cancer

January 11th 2020

Combining Anti-HER2 Agents With Immunotherapy for HER2+ mBC

January 11th 2020

Emerging Agents for HER2+ mBC: Targeted Therapeutics

January 11th 2020

Emerging Agents for HER2+ mBC: HER2CLIMB and SOPHIA Trials

January 11th 2020

Evolving Role of Trastuzumab Deruxtecan in HER2+/HER2-Low mBC

January 11th 2020

HER2+ mBC: Addressing ILD in the DESTINY-Breast01 Study

January 11th 2020

HER2+ mBC: Study Design and Results of DESTINY-Breast01

January 11th 2020

HER2+ Breast Cancer: Evolution of Antibody-Drug Conjugates

January 11th 2020

Unmet Needs in the Management of HER2+ mBC

January 11th 2020

Treatment Strategies for Relapsed/Refractory HER2+ mBC

January 11th 2020

HER2+ BC: Selection and Management of Neoadjuvant Therapy

January 11th 2020

Overview of Neoadjuvant Therapy in HER2+ Breast Cancer

January 11th 2020

Early-Stage HER2+ Breast Cancer: The ATEMPT Trial

January 11th 2020

Impact of the KATHERINE Trial on Early-Stage HER2+ BC

January 11th 2020